BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations
Ongoing Clinical Development Program Represents Largest and Longest Development Program for any Gene Therapy in Hemophilia A, Demonstrates Commitment to Advancing Care for People with Hemophilia A
SAN RAFAEL, Calif., May 5, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced five platform presentations and one poster presentation on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the World Federation of Hemophilia (WFH) 2022 World Congress from May 8-11 in Montreal, Canada.
"We're pleased to provide updated data on durability of effect in patients treated over two years ago, on molecular contributors to variability, on hepatotoxicity and the role of immunosuppression, on the potential for integration-related oncogenicity, and on health-related quality of life. We continue to learn about the potential for investigational valoctocogene roxaparvovec to transform lives and the optimal way to manage patients through their journey," said Hank Fuchs, M.D., President of Worldwide Research and Development at BioMarin. "We are progressing our regulatory efforts with the intent to deliver a therapy that may represent an important and valuable treatment choice for patients with severe Hemophilia A, as no presently available treatment offers such freedom from prophylaxis and reduced bleeding frequency at the same time."
"BioMarin is generating valuable data about investigational valoctocogene roxaparvovec that potentially could enable shared decision making between physicians and patients on what is the best therapy in each personal situation," said Professor Wolfgang Miesbach, Head of the Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre at the Goethe University Hospital in Frankfurt/Main, Germany.
Presentation of data at WFH follows positive two-year results from the ongoing, global phase 3 GENEr8-1 study of valoctocogene roxaparvovec presented at a medical meeting earlier in the year, as well as publication of one-year results from the pivotal clinical trial in the New England Journal of Medicine in March 2022.
BioMarin's presentations at WFH include:
Platform Presentations
Immune suppression following gene therapy in HemophiliaProfessor Wolfgang Miesbach, Head of the Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre, Goethe University Hospital, Frankfurt/Main, GermanyMonday, May 9, 2022, 1:30 -2:30 PM ET
Exploratory analyses of healthy liver biopsies and a single case of parotid acinar cell carcinoma do not identify a role for valoctocogene roxaparvovec vector insertion in altering cell growthKevin Eggan, Group Vice President, Head of Research and Early Development / BioMarinMonday, May 9, 2022, 1:30 -2:30 PM ET
Health-related quality of life over 2 years following valoctocogene roxaparvovec adeno-associated virus gene transfer for severe hemophilia A: Results from GENEr8-1Dr. Amy Dunn, Director of Pediatric Hematology, Nationwide Children's Hospital, Columbus, OhioTuesday, May 10, 2022, 1:30-2:30 PM ET
Human liver biopsy analysis showed interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A Sylvia Fong, Head of Hematology Research, BioMarinWednesday, May 11, 2022, 1:30 -2:30 PM ET
Interim 52-week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A Brian Long, Principal Scientist, Clinical Immunology, BioMarinWednesday, May 11, 2022, 4-5 PM ET
Poster Presentation
Use of immunosuppressives in patients with hemophilia receiving gene therapy: Evidence generation using a mixed-methods approach Professor Wolfgang Miesbach, Head of the Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre, Goethe University Hospital, Frankfurt/Main, Germany
BioMarin-Sponsored Symposia
Gene Therapy Clinical Trial Patient Journey: A Look Into Shared Decision MakingMonday, May 9, 12:15 1:15 PM ET
About Hemophilia A
People living with hemophilia A lack sufficient functioning Factor VIII protein to help their blood clot and are at risk for painful and/or potentially life-threatening bleeds from even modest injuries. Additionally, people with the most severe form of hemophilia A (FVIII levels <1%) often experience painful, spontaneous bleeds into their muscles or joints. Individuals with the most severe form of hemophilia A make up approximately 50 percent of the hemophilia A population. People with hemophilia A with moderate (FVIII 1-5%) or mild (FVIII 5-40%) disease show a much-reduced propensity to bleed. The standard of care for individuals with severe hemophilia A is a prophylactic regimen of replacement Factor VIII infusions administered intravenously up to two to three times per week or 100 to 150 infusions per year. Despite these regimens, many people continue to experience breakthrough bleeds, resulting in progressive and debilitating joint damage, which can have a major impact on their quality of life.
Hemophilia A, also called Factor VIII deficiency or classic hemophilia, is an X-linked genetic disorder caused by missing or defective Factor VIII, a clotting protein. Although it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous mutation, a new mutation that was not inherited. Approximately 1 in 10,000 people have Hemophilia A.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. For additional information, please visitwww.biomarin.com.
Forward Looking Statements
This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including without limitation, statements about: the data presented at WFH, including the five platform presentations, one poster, and one BioMarin sponsored symposia, the development of BioMarin's valoctocogene roxaparvovec program generally, the impact of valoctocogene roxaparvovec gene therapy for treating patients with severe hemophilia A and the potential to transform the lives of these patients and the ongoing clinical programs generally. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: results and timing of current and planned preclinical studies and clinical trials of valoctocogene roxaparvovec, including final analysis of the above data and additional data from the continuation of these trials and the entire development program, including further assessment of safety events, any potential adverse events observed in the continuing monitoring of the patients in the clinical trials; the content and timing of decisions by the FDA, the EMA and other regulatory authorities; the content and timing of decisions by local and central ethics committees regarding the clinical trials; our ability to successfully manufacture valoctocogene roxaparvovec; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission (SEC), including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 as such factors may be updated by any subsequent reports. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioMarin is a registered trademark of BioMarin Pharmaceutical Inc.
Contacts:
Investors
Media
Traci McCarty
Debra Charlesworth
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
(415) 455-7558
(415) 455-7451
SOURCE BioMarin Pharmaceutical Inc.
The rest is here:
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia...
- 001 Faulty Circuits (preview) [Last Updated On: April 7th, 2010] [Originally Added On: April 7th, 2010]
- 002 Faulty Circuits (preview) [Last Updated On: April 7th, 2010] [Originally Added On: April 7th, 2010]
- 003 Rare flowers and common herbal supplements get unmasked with plant DNA barcoding [Last Updated On: April 20th, 2010] [Originally Added On: April 20th, 2010]
- 004 Rare flowers and common herbal supplements get unmasked with plant DNA barcoding [Last Updated On: April 20th, 2010] [Originally Added On: April 20th, 2010]
- 005 Biomarker Studies Could Realize Goal of More Effective and Personalized Cancer Medicine [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- 006 Biomarker Studies Could Realize Goal of More Effective and Personalized Cancer Medicine [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- 007 Schizophrenia shares genetic links with autism, genome study shows [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- 008 Schizophrenia shares genetic links with autism, genome study shows [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- 009 Alzheimer's: Forestalling the Darkness with New Approaches (preview) [Last Updated On: May 28th, 2010] [Originally Added On: May 28th, 2010]
- 010 Alzheimer's: Forestalling the Darkness with New Approaches (preview) [Last Updated On: May 28th, 2010] [Originally Added On: May 28th, 2010]
- 011 Large-Scale Autism Study Reveals Disorder's Genetic Complexity [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 012 Large-Scale Autism Study Reveals Disorder's Genetic Complexity [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 013 Cancer Therapy Goes Viral: Progress Is Made Tackling Tumors with Viruses [Last Updated On: June 24th, 2010] [Originally Added On: June 24th, 2010]
- 014 Cancer Therapy Goes Viral: Progress Is Made Tackling Tumors with Viruses [Last Updated On: June 24th, 2010] [Originally Added On: June 24th, 2010]
- 015 Vaccines Derived from Patients' Tumor Cells Are Individualizing Cancer Treatment [Last Updated On: June 26th, 2010] [Originally Added On: June 26th, 2010]
- 016 Vaccines Derived from Patients' Tumor Cells Are Individualizing Cancer Treatment [Last Updated On: June 26th, 2010] [Originally Added On: June 26th, 2010]
- 017 A genome story: 10th anniversary commentary by Francis Collins [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 018 A genome story: 10th anniversary commentary by Francis Collins [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 019 Hair Trigger: How a Cell's Primary Cilium Functions as a Molecular Antenna [Last Updated On: June 30th, 2010] [Originally Added On: June 30th, 2010]
- 020 Hair Trigger: How a Cell's Primary Cilium Functions as a Molecular Antenna [Last Updated On: June 30th, 2010] [Originally Added On: June 30th, 2010]
- 021 DNA Drugs Come of Age (preview) [Last Updated On: July 16th, 2010] [Originally Added On: July 16th, 2010]
- 022 DNA Drugs Come of Age (preview) [Last Updated On: July 16th, 2010] [Originally Added On: July 16th, 2010]
- 023 2 Genes Linked to Embryonic Brain Impairment in Down's Syndrome [Last Updated On: July 22nd, 2010] [Originally Added On: July 22nd, 2010]
- 024 2 Genes Linked to Embryonic Brain Impairment in Down's Syndrome [Last Updated On: July 22nd, 2010] [Originally Added On: July 22nd, 2010]
- 025 Stem Cells from Reprogrammed Adult Cells Found to Bring Along Genetic Defects of Their Donors [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 026 Was Darwin a Punk? A Q&A with Punker-Paleontologist Greg Graffin [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 027 Parkinsonian Power Failure: Neuron Degeneration May Be Caused by a Cellular Energy System Breakdown [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 028 Stem Cells from Reprogrammed Adult Cells Found to Bring Along Genetic Defects of Their Donors [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 029 Was Darwin a Punk? A Q&A with Punker-Paleontologist Greg Graffin [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 030 Parkinsonian Power Failure: Neuron Degeneration May Be Caused by a Cellular Energy System Breakdown [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 031 Desperation Drives Parents to Dubious Autism Treatments (preview) [Last Updated On: October 13th, 2010] [Originally Added On: October 13th, 2010]
- 032 Desperation Drives Parents to Dubious Autism Treatments (preview) [Last Updated On: October 17th, 2010] [Originally Added On: October 17th, 2010]
- 033 Revolution Postponed: Why the Human Genome Project Has Been Disappointing (preview) [Last Updated On: October 21st, 2010] [Originally Added On: October 21st, 2010]
- 034 Controlling the Brain with Light (preview) [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 035 Optogenetics: Controlling the Brain with Light [Extended Version] [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 036 Clear New Insights into the Genetics of Depression [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 037 TEDMED 2010: Technology and the people [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 038 Bacteria, the anti-cancer soldier [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 039 Revolution Postponed: Why the Human Genome Project Has Been Disappointing (preview) [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 040 Controlling the Brain with Light (preview) [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 041 Optogenetics: Controlling the Brain with Light [Extended Version] [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 042 Clear New Insights into the Genetics of Depression [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 043 TEDMED 2010: Technology and the people [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 044 Bacteria, the anti-cancer soldier [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 045 Scientific regress: When science goes backward [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 046 Can You Live Forever? Maybe Not--But You Can Have Fun Trying [Last Updated On: January 1st, 2011] [Originally Added On: January 1st, 2011]
- 047 How to Fix the Obesity Crisis (preview) [Last Updated On: January 22nd, 2011] [Originally Added On: January 22nd, 2011]
- 048 Scientific regress: When science goes backward [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 049 Can You Live Forever? Maybe Not--But You Can Have Fun Trying [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 050 How to Fix the Obesity Crisis (preview) [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 051 Personalizing cancer medicine [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 052 New Salmonella strain delivers gene-based therapy to fight virus in mice [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 053 Personalizing cancer medicine [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 054 New Salmonella strain delivers gene-based therapy to fight virus in mice [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 055 Steps toward a Bionic Eye [Last Updated On: February 18th, 2011] [Originally Added On: February 18th, 2011]
- 056 Steps toward a Bionic Eye [Last Updated On: February 20th, 2011] [Originally Added On: February 20th, 2011]
- 057 Giving HIV a Poor Reception: New AIDS Treatment Tinkers with Immune Cell Genes [Last Updated On: March 6th, 2011] [Originally Added On: March 6th, 2011]
- 058 Giving HIV a Poor Reception: New AIDS Treatment Tinkers with Immune Cell Genes [Last Updated On: March 6th, 2011] [Originally Added On: March 6th, 2011]
- 059 Smaller, cheaper, faster: Does Moore's law apply to solar cells? [Last Updated On: March 27th, 2011] [Originally Added On: March 27th, 2011]
- 060 Smaller, cheaper, faster: Does Moore's law apply to solar cells? [Last Updated On: March 27th, 2011] [Originally Added On: March 27th, 2011]
- 061 New Drugs for Hepatitis C on the Horizon [Last Updated On: April 10th, 2011] [Originally Added On: April 10th, 2011]
- 062 Can we capture all of the world's carbon emissions? [Last Updated On: April 10th, 2011] [Originally Added On: April 10th, 2011]
- 063 New Drugs for Hepatitis C on the Horizon [Last Updated On: April 10th, 2011] [Originally Added On: April 10th, 2011]
- 064 Can we capture all of the world's carbon emissions? [Last Updated On: April 10th, 2011] [Originally Added On: April 10th, 2011]
- 065 Drug-resistant genes found in cholera and dysentery strains in New Delhi water supply [Last Updated On: May 1st, 2011] [Originally Added On: May 1st, 2011]
- 066 Fast Track to Vaccines: How Systems Biology Speeds Drug Development (preview) [Last Updated On: May 1st, 2011] [Originally Added On: May 1st, 2011]
- 067 Drug-resistant genes found in cholera and dysentery strains in New Delhi water supply [Last Updated On: May 1st, 2011] [Originally Added On: May 1st, 2011]
- 068 Fast Track to Vaccines: How Systems Biology Speeds Drug Development (preview) [Last Updated On: May 1st, 2011] [Originally Added On: May 1st, 2011]
- 069 Autism's Tangled Genetics Full of Rare and Varied Mutations [Last Updated On: June 19th, 2011] [Originally Added On: June 19th, 2011]
- 070 A New Look at Obsessive-Compulsive Disorder (preview) [Last Updated On: June 19th, 2011] [Originally Added On: June 19th, 2011]
- 071 Autism's Tangled Genetics Full of Rare and Varied Mutations [Last Updated On: June 19th, 2011] [Originally Added On: June 19th, 2011]
- 072 A New Look at Obsessive-Compulsive Disorder (preview) [Last Updated On: June 19th, 2011] [Originally Added On: June 19th, 2011]
- 073 Close Encounters of Science and Medicine [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 074 Close Encounters of Science and Medicine [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 075 New Report Details Uphill Battle to Solve the U.S.'s Pain Problem [Last Updated On: July 24th, 2011] [Originally Added On: July 24th, 2011]
- 076 New Report Details Uphill Battle to Solve the U.S.'s Pain Problem [Last Updated On: July 24th, 2011] [Originally Added On: July 24th, 2011]
- 077 A Breath of Fresh Air: New Hope for Cystic Fibrosis Treatment (preview) [Last Updated On: August 7th, 2011] [Originally Added On: August 7th, 2011]
- 078 A Breath of Fresh Air: New Hope for Cystic Fibrosis Treatment (preview) [Last Updated On: August 7th, 2011] [Originally Added On: August 7th, 2011]
- 079 Gene therapy improves stem cell transplantation - Video [Last Updated On: October 13th, 2011] [Originally Added On: October 13th, 2011]
- 080 THE NEW MORGELLONS HAIR - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]